J Biol Chem, Vol. 275, Issue 1, 135-140, January 7, 2000
Inhibition of Escherichia coli
Glucosamine-6-phosphate Synthase by Reactive Intermediate Analogues
THE ROLE OF THE 2-AMINO FUNCTION IN CATALYSIS*
Stephen L.
Bearne
and
Christian
Blouin
From the Department of Biochemistry and Molecular Biology,
Dalhousie University, Halifax, Nova Scotia B3H 4H7, Canada
 |
ABSTRACT |
Glucosamine-6-phosphate synthase (GlmS) catalyzes
the formation of D-glucosamine 6-phosphate from
D-fructose 6-phosphate using L-glutamine as the
ammonia source. Because N-acetylglucosamine is an essential
building block of both bacterial cell walls and fungal cell wall
chitin, the enzyme is a potential target for antibacterial and
antifungal agents. The most potent carbohydrate-based inhibitor of GlmS
reported to date is 2-amino-2-deoxy-D-glucitol 6-phosphate,
an analogue of the putative cis-enolamine intermediate formed during catalysis. The interaction of a series of structurally related cis-enolamine intermediate analogues with GlmS is
described. Although arabinose oxime 5-phosphate is identified as a good
competitive inhibitor of GlmS with an inhibition constant equal to 1.2 (±0.3) mM, the presence of the amino function at the
2-position is shown to be important for potent inhibition. Comparison
of the binding affinities of 2-deoxy-D-glucitol 6-phosphate
and 2-amino-2-deoxy-D-glucitol 6-phosphate
indicates that the amino function contributes
4.1 (±0.1) kcal/mol to
the free energy of inhibitor binding. Similarly, comparison of the
binding affinities of 2-deoxy-D-glucose 6-phosphate and
D-glucosamine 6-phosphate indicates that the amino function contributes
3.0 (±0.1) kcal/mol to the free energy of product binding. Interactions between GlmS and the 2-amino function of its
ligands contribute to the uniform binding of the product and the
cis-enolamine intermediate as evidenced by the similar
contribution of the amino group to the free energy of binding of
D-glucosamine 6-phosphate and
2-amino-2-deoxy-D-glucitol 6-phosphate, respectively.
 |
INTRODUCTION |
Glucosamine-6-phosphate synthase (L-glutamine:
D-fructose-6-phosphate aminotransferase
(GlmS,1 EC 2.6.1.16))
catalyzes the first step in hexosamine biosynthesis, converting
D-fructose 6-phosphate (Fru-6-P) into
D-glucosamine 6-phosphate (GlcN-6-P) using glutamine as the
ammonia source (Scheme 1) (1-3).
GlcN-6-P is a precursor of uridine
diphospho-N-acetylglucosamine from which other amino
sugar-containing molecules are derived. One of these products,
N-acetylglucosamine, is an important constituent of the
peptidoglycan layer of bacterial cell walls and fungal cell wall
chitin. Accordingly, GlmS offers a potential target for antibacterial
and antifungal agents and has attracted the interest of several
research groups (2).
GlmS catalyzes two coupled enzymatic reactions. The first is the
hydrolysis of glutamine to yield glutamate and nascent ammonia, which
is transferred to Fru-6-P. The second reaction is the isomerization of
Fru-6-P from a ketose to an aldose, corresponding to a Heyns rearrangement (4, 5). Like other amidotransferases, GlmS is organized
into two domains: the NH2-terminal glutamine
amidotransferase domain, which catalyzes the hydrolysis of glutamine,
and the COOH-terminal synthase domain, which catalyzes the
isomerization (3, 6-8). The glutamine hydrolysis reaction has been
studied extensively and utilizes the NH2-terminal cysteine
thiol, which forms a
-glutamyl thioester intermediate during the
reaction. This catalytic role was confirmed by conversion of the
NH2-terminal cysteine to alanine using site-directed
mutagenesis which abolished enzymatic activity (2). In general,
glutamine amidotransferases are inactivated by glutamine affinity
analogues such as 6-diazo-5-oxo-L-norleucine and
6-chloro-5-oxo-L-norleucine (chloroketone), which alkylate the essential cysteine residue (3, 7, 9). Indeed, many of the active
site-directed irreversible inactivators developed for GlmS contain an
electrophilic function at the
-position of glutamate and react
irreversibly with the NH2-terminal cysteine residue. More
recently, attempts to develop carbohydrate-based inhibitors have been
made with the hope of developing more specificity (10-13).
The ketose/aldose isomerase activity of the enzyme proceeds by
abstraction of the C1 pro-R hydrogen of a putative
fructosimine 6-phosphate intermediate to form a
cis-enolamine reactive intermediate that, upon reprotonation
at the Re face of C2, gives rise to GlcN-6-P (Scheme
2) (5). In accord with this mechanism,
Badet and co-workers (14) have shown that GlmS, in the absence of
glutamine, displays a low phosphoglucoisomerase activity. Analogues of
the cis-enolamine reactive intermediate are expected to be
potent inhibitors of the enzyme (15-18) and indeed,
2-amino-2-deoxy-D-glucitol 6-phosphate (GlcNol-6-P) is the
most potent carbohydrate-based inhibitor reported to date (11, 12).
Identification of those structural elements necessary for tight binding
is an important part of inhibitor design. This paper describes the
inhibition of GlmS by several analogues of the cis-enolamine intermediate in an attempt to probe the structural requirements for
potent inhibition of this enzyme. The energetic contribution of the
2-amino group to binding of the product and the
cis-enolamine intermediate is determined.
 |
MATERIALS AND METHODS |
D-Arabinose, D-arabinose 5-phosphate,
2-amino-2-deoxy-D-glucose 6-phosphate
(D-glucosamine 6-phosphate), 2-deoxy-D-glucose 6-phosphate (dGlc-6-P), D-Fru-6-P, and D-ribose
5-phosphate were purchased from Sigma Chemical Company. All other
chemicals were analytical grade and used without further purification.
NMR spectra (13C, 31P) were obtained using a
Bruker AC 250F spectrometer. Chemical shifts (
) for 13C
and 31P spectra are reported relative to the deuterium lock
signal and external H3PO4 (85% w/v in
D2O), respectively. Elemental analyses were performed by
Canadian Microanalytical Service Ltd., B. C.
2-Deoxy-D-glucitol
6-Phosphate--
2-Deoxy-D-glucitol 6-phosphate
(dGlcol-6-P) was synthesized by reduction of
2-deoxy-D-glucose 6-phosphate (dGlc-6-P) with sodium
borohydride and purified by ion-exchange chromatography following
procedures similar to those outlined for the preparation of GlcNol-6-P
(12). dGlc-6-P (250 mg, 0.868 mmol) was dissolved in 10 ml of water and
cooled on ice for 10 min. Sodium borohydride (0.750 g, 19.83 mmol) was
added to the dGlc-6-P solution by small portions over 20 min. During
the NaBH4 addition, the solution was stirred vigorously and
held on ice. After the addition was complete, the solution was stirred
for 1 h at room temperature. Reduction was complete as indicated
by the inability of the solution to reduce Fehling's reagent.
Undissolved NaBH4 was removed by filtration, and the
filtrate was cooled on ice. The remaining NaBH4 was
destroyed by dropwise addition of 6 M acetic acid over 30 min until the final pH was approximately 4. The solution (25 ml) was
allowed to come to room temperature and stirred for 1 h. This
solution was then filtered, and the filtrate was applied to a Dowex 50 (H+ form) column (1.5 × 47 cm) and eluted with water.
Fractions containing product were identified by thin layer
chromatography on cellulose (99% EtOH, n-BuOH, 0.15 M sodium citrate buffer, pH 4.0; 10:1:6 v/v/v) developed
with an iron-sulfosalicylic acid spray reagent (19) sensitive to
phosphates. Fractions testing positive for phosphate were pooled and
diluted with 0.50 volume of methanol. The solvent was then removed
using rotary evaporation (
37 °C) and freed of borate by repeated
treatment with methanol followed by removal of the methanol and
methylborate ester by rotary evaporation. The remaining clear syrup was
taken up in 10 ml of water and applied to a Dowex 50 (H+
form) column (1.5 × 47 cm) eluted with water. Fractions
containing dGlcol-6-P were combined and lyophilized yielding a
hygroscopic glassy powder (0.1953 g, 78% yield). 13C NMR
(62.896 MHz, D2O)
38.00 (s, C2), 61.36 (s,
C1), 69.18 (d, JC, P = 4.77 Hz,
C6), 69.43 (s, C3), 72.77 (d,
JC, P = 7.63 Hz, C5), 75.03 (s,
C4); 31P NMR (101.26 MHz, D2O)
decoupled 1.93 (s) and coupled 1.93 (t, JH, P = 5.72 Hz). The disodium salt was converted to the less hygroscopic
monocyclohexylammonium salt using Dowex 50 (cyclohexylammonium form).
Elemental analysis was as follows.
|
|
|
|
|
|
|
|
D-Arabinose Oxime
5-Phosphate--
D-Arabinose oxime was prepared by
treating D-arabinose with hydroxylamine as described by
Finch and Merchant (20, 21) and Hockett et al. (22, 23). The
oxime was then converted to its corresponding 5-phosphate using
hexokinase-catalyzed phosphorylation as described by Finch and Merchant
(20). The proton-coupled 31P NMR spectrum of the
enzymatically synthesized and isolated D-arabinose oxime
5-phosphate showed broad triplets centered at 5.74 ppm
(JH, P = 7.3 Hz) and 4.90 ppm
(JH, P = 4.4 Hz). These signals were assigned to
the phosphorus nuclei coupled to H-5a,5b in the E and
Z oxime phosphate, respectively, similar to the
31P NMR assignments reported by Finch and Merchant (20).
There were also five very minor peaks (
7%) present at 3.58,
4.74,
4.92,
9.07, and
9.29 possibly due to contaminating
phosphoenolpyruvate or nucleotides. The actual concentration of
D-arabinose oxime 5-phosphate used in the inhibition
studies was determined by integration of the 1H NMR
spectrum. The well resolved doublets at 7.59 ppm and 6.95 ppm arising
from H-1 of the E and Z forms were integrated
relative to an internal pyrazine standard. The ratio of E to
Z oxime determined using 1H NMR was 85:15,
respectively, which is in agreement with the reported ratio of 83:17
(20).
Enzyme Purification and Assays--
GlmS was purified as
described earlier (12, 24). The specific activity of the final
preparation was 0.25 unit/mg of protein. GlcN-6-P was determined using
a modified Morgan-Elson procedure, and the validity of the assay was
established as described previously (12, 24). Inorganic and organic
phosphate assays were conducted according to the procedures described
by Leloir and Cardini (25).
Inhibition Studies--
Assays were conducted in 0.1 M potassium phosphate buffer, pH 7.5, containing 1 mM EDTA. The concentration of inhibitors used in the assays
were as follows: D-arabinose 5-phosphate, 4.6, 9.1, and
13.7 mM; D-arabinose oxime 5-phosphate, 3.1, 6.2, and 9.4 mM; D-ribose 5-phosphate, 9.1, 18.2, and 27.3 mM; dGlcol-6-P, 25.0 and 50.0 mM; and dGlc-6-p, 57.2 and 171.7 mM. In
addition, the assays contained GlmS (6.7 × 10
3
unit/ml), L-glutamine (15 mM), and
D-Fru-6-P at concentrations equal to 0.45, 0.89, 1.79, 4.47, and 8.94 mM. GlmS was found to be relatively
insensitive to changes in ionic strength, and therefore no attempt was
made to correct for changes in ionic strength. Complete
Michaelis-Menten plots were constructed at all inhibitor concentrations
using the concentrations of D-Fru-6-P given above. Kinetic
data were analyzed by nonlinear regression analysis of the
Michaelis-Menten plots using the program Enzymekinetics
(1990) from Trinity Software. The inhibition constants were determined in triplicate, and the average value is reported. The reported error is
the S.D.
 |
RESULTS AND DISCUSSION |
Much attention has been focused on utilizing glutamine analogues
to inhibit GlmS activity with the goal of developing antibacterial and
antifungal agents. Typically, these analogues possess an electrophilic function at the
-position of glutamate, which is believed to react
irreversibly with the NH2-terminal cysteine residue located in the glutamine amidotransferase domain. The most effective
inactivators have been
N3-fumaroyl-L-2,3-diaminopropanoate
derivatives (26-29) and
2-amino-3-((N-halomethyl)amino)propanoate derivatives (30,
31). Although the enzyme is believed to follow an ordered Bi Bi kinetic
mechanism (27), glutamine-like inactivators bind and inactivate GlmS
effectively even in the absence of the first substrate Fru-6-P (26,
27).
Recently, there has been an effort to identify carbohydrate-based
inhibitors specific for GlmS (10-13). One approach to developing potent enzyme inhibitors is to design compounds that are analogues of
either the transition states or reactive intermediates that are formed
during catalysis (15-18). The mechanisms of phosphorylated sugar
isomerases that catalyze the interconversion of an aldose and a ketose
have been shown to involve proton abstraction from either substrate to
give an enzyme-bound cis-enediol intermediate (32, 33).
Virtually all of these enzymes show activity in the absence of metal
ions and have exchange (to solvent) to intramolecular hydrogen transfer
ratios greater than 1 (33, 34). As expected, analogues of the
cis-enediol are potent inhibitors of such isomerases (18).
For example, triose-phosphate isomerase is inhibited by 2-phosphoglycolate and 2-phosphoglycolohydroxamate (35, 36), glucose-6-phosphate isomerase is inhibited by 5-phosphoarabinoate (37),
and both arabinose-5-phosphate isomerase and ribose-5-phosphate epimerase are inhibited by 4-phosphoerythronate (38, 39). To the extent
that the transition state for the rate-determining step resembles an
enediol, these analogues may be considered transition state analogues.
A similar mechanism has been described for both glucosamine-6-phosphate
deaminase (40) and GlmS (5) where proton abstraction from the substrate
yields an enzyme-bound cis-enolamine intermediate (Scheme
2). In accord with this mechanism, both the deaminase (40) and the
synthase (5) have exchange (to solvent) to intramolecular hydrogen
transfer ratios greater than 1, similar to the phosphosugar isomerases
discussed above. In addition, GlcNol-6-P, an analogue of the
cis-enolamine intermediate, is a potent inhibitor of both
enzymes (11, 12, 40). In fact, GlcNol-6-P is the tightest binding
reversible carbohydrate-based inhibitor reported for GlmS. The present
work describes the inhibition of Escherichia coli GlmS by
several analogues of the cis-enolamine intermediate and the
energetic contribution that the 2-amino function makes to ligand binding.
Inhibition by Reactive Intermediate Analogues--
The structures
of several analogues of the putative cis-enolamine
intermediate and their corresponding inhibition constants (Ki) are shown in Table
I. In all cases, the analogues were found
to be competitive inhibitors of GlmS activity with respect to Fru-6-P.
The values of the inhibition constants should be accurate estimates of
the dissociation constants for these inhibitors since the
Ki value for GlcNol-6-P (19 µM) was
shown to be very similar to the dissociation constant of 34 (±7)
µM determined for this ligand using protection
experiments (12). The carbonyl functions present in the open chain
forms of arabinose 5-phosphate and ribose 5-phosphate mimic the double bond present in the cis-enolamine. That the enzyme displays
a low affinity for both of these compounds relative to GlcNol-6-P indicates that the 2-amino and 1-hydroxyl functions are important for
tight binding of GlcNol-6-P. Changing the stereochemistry at C2 causes
approximately a 4-fold reduction in the binding of ribose 5-phosphate
relative to arabinose 5-phosphate. This observation is not unexpected
because enzymes that isomerize carbohydrate substrates generally show
such stereochemical discrimination (41).
Table I shows both arabinose 5-phosphate and ribose 5-phosphate in
their acyclic free carbonyl forms so that their structural similarity
to the cis-enolamine intermediate is evident. However, in
neutral aqueous solution, the acyclic forms of arabinose 5-phosphate and ribose 5-phosphate only comprise approximately 2.4 and 0.6% of the
total concentration of species present, respectively (42). Under
similar conditions, Fru-6-P exists in the
-furanose (81.1%),
-furanose (16.1%), and free carbonyl (2.2%) forms (42). Whether the cyclic or acyclic form of Fru-6-P is the actual substrate for GlmS
is not known. Badet-Denisot et al. (2) have argued that
there is no need for GlmS to catalyze ring opening because the
spontaneous rate of ring opening of Fru-6-P (18-21 s
1;
Ref. 42) is similar to the catalytic rate (19-23 s
1).
However, other phosphosugar isomerases that proceed via an enolization
mechanism such as glucose-6-phosphate isomerase (43-45), mannose-6-phosphate isomerase (46), and GlcN-6-P deaminase (47), are
believed to catalyze ring opening of the cyclic carbohydrate substrate
to form the corresponding straight chain species prior to
deprotonation. Recently, the crystal structures of complexes of the
GlmS Fru-6-P binding domain (8) with different ligands have been
reported, including Glu-6-P (48), GlcN-6-P (48), and GlcNol-6-P (49).
Based on these crystal structures, Teplyakov and co-workers (48, 49)
have proposed that GlmS uses His-504 as a general base to catalyze ring
opening of cyclic Fru-6-P. Thus it is possible that GlmS may catalyze
the ring opening of arabinose 5-phosphate and ribose 5-phosphate.
Arabinose 5-phosphate exists in the
-furanose (57.3%),
-furanose
(40.4%), hydrate (2.2%), and free carbonyl (
0.2%) forms in
neutral aqueous solution (40). If the free aldehyde were the actual
inhibitory species, adjustment of the observed inhibition constant to
reflect the concentration of free carbonyl present in solution would
yield an upper limit for the Ki value equal to 17 µM. However, there seems to be no convincing reason to
adjust the observed inhibition constant in this manner.
Arabinose oxime 5-phosphate is an analogue of the
cis-enolamine that contains the double bond and the hydroxyl
function but lacks the 2-amino function. GlmS binds this analogue with
an apparent inhibition constant equal to 1.2 mM,
approximately 7-fold less than the Ki value observed
for arabinose 5-phosphate. It is important to note that the inhibition
mixture tested was an equilibrium mixture containing 15% of the
anti (Z) form and 85% of the syn
(E) form, the latter being analogous to the
cis-enolamine intermediate. Adjusting the apparent
Ki value to reflect the concentration of the
E form present in solution gives a Ki value equal to 1.0 mM. The affinity that GlmS displays for
the oxime is still 53-fold less than the affinity with which GlmS binds
GlcNol-6-P. Is this lack of binding affinity principally due to the
missing amino function? Replacement of the hydrogen on C2 of the oxime
with an amino group would yield a compound that differs from the
cis-enolamine intermediate by only the substitution of a
nitrogen at C1. Because the amino function contributes approximately 4.1 kcal/mol to the binding affinity (see below), the expected Ki value for such a compound would be approximately
1.3 µM. This value is approximately 15-fold less than the
Ki value for GlcNol-6-P and might serve as an
estimate of the upper limit for the enzyme's affinity for the actual
cis-enolamine intermediate.
Corizzi et al. (10) have reported that the non-isosteric
phosphonate analogue of Fru-6-P is a poor competitive inhibitor of GlmS
with respect to Fru-6-P (Ki = 2.5 mM).
However, the oxime of this compound was reported to have a much higher affinity for the enzyme with a Ki value equal to 0.2 mM (10), which is slightly less than the inhibition
constant observed for arabinose oxime 5-phosphate in the present work. This is unexpected because, unlike the arabinose derived oxime, the
oxime of the phosphonate is not isosteric with the putative cis-enolamine intermediate. One explanation for this
difference in binding affinities may be that the oxime of the
phosphonate exists more predominately in the Z form.
Unfortunately, the relative amounts of E and Z
forms were not reported for the oxime of the phosphonate. Despite the
difference in binding affinities, the inhibitory nature of the oximes
reflects their structural similarity to the proposed
cis-enolamine intermediate.
Contribution of the Amino Group to Ligand Binding--
The
interactions between an enzyme and a ligand always involve a
substantial number of groups. The general approach to understanding the
observed affinity has been to dissect it into the contributions of each
group by measuring the change in affinity which results when one of the
groups of interest is removed (50-52). This type of analysis may be
conducted by removing a group from either the enzyme using
site-directed mutagenesis or from the ligand (51, 53). When the latter
approach is used, the kcat/Km values observed with the natural substrate and a modified substrate may
be compared by calculating the effect of the modification on the free
energy of the transition state relative to the ground state.
Alternatively, transition state analogue inhibitors may be modified and
the subsequent changes in binding affinity interpreted as the
contribution of the removed moiety to transition state binding (54).
This latter approach is used in the present work to assess the
contribution that the 2-amino function makes to the binding of the
product (GlcN-6-P) and the reactive intermediate analogue (GlcNol-6-P).
2-Deoxy-D-glucose 6-phosphate, which differs from GlcN-6-P
by the absence of an amino function at the 2-position, is only weakly
bound by the enzyme (Ki = 46 ± 7 mM). This corresponds to a free energy of binding
(
GdGlc-6-P) equal to
1.90 ± 0.09 kcal/mol compared with a value of
4.85 kcal/mol observed for the
binding free energy of GlcN-6-P (
GGlcN-6-P)
(27).2 Thus the 2-amino
function contributes
3.0 ± 0.1 kcal/mol
(
G =
GGlcN-6-P
GdGlc-6-P) to the free energy of product
binding. Similarly, dGlcol-6-P, which differs from GlcNol-6-P by the
absence of an amino function at the 2-position, is also only bound
weakly by the enzyme (Ki = 15 ± 2 mM). This corresponds to a free energy of binding
(
GdGlcol-6-P) equal to
2.59 ± 0.08 kcal/mol compared with a value of
6.70 ± 0.02 kcal/mol observed
for the binding free energy of GlcNol-6-P (
GGlcNol-6-P) (12). Thus the 2-amino function
contributes
4.1 ± 0.1 kcal/mol (
G =
GGlcNol-6-P
GdGlcol-6-P) to the free energy of reactive
intermediate analogue binding. These values are similar to the binding
free energies reported for amino functions participating in other
protein-ligand interactions. For example, 
G values of
3.4 kcal/mol and
6.7 kcal/mol have been reported for the binding
contribution of the amino function on ligands interacting with the
enzymes phenylalanyl-tRNA synthetase (55, 56) and isoleucyl-tRNA
synthetase (57), respectively. For the aminoglycoside
3'-phosphotransferases, types Ia and IIa, values as large as
6 to
11 kcal/mol have been reported for the energetic contribution of the
amino function to the stabilization of transition state species
(
G =
RTln((kcat/Km)H/(kcat/Km)NH2))
(58).
Thus, the amino function at the 2-position contributes approximately
the same amount of binding energy to the binding of the product,
GlcN-6-P, as it does to the binding of the reactive intermediate analogue, GlcNol-6-P. The amino function, therefore, contributes to the
uniform binding (59, 60) of both the product and the cis-enolamine intermediate. Selective stabilization of the
cis-enolamine intermediate relative to the ground state must
therefore be caused by another binding determinant, likely the hydroxyl
function at C1.
Protein Interaction with the 2-Amino Group--
The structures of
enzymes complexed to substrates, products, and transition state or
reactive intermediate analogues are often useful in delineating the
role of enzyme-ligand interactions in catalysis (61). The crystal
structures of complexes of the Fru-6-P binding domain of GlmS (8) with
GlcN-6-P (48) and GlcNol-6-P (49) show the interactions between the
2-amino group and the isomerase domain which give rise to the observed
uniform binding (Fig. 1). The amino group
of GlcN-6-P is hydrogen bonded to the carbonyls of Val-399 and Ala-602,
and to a water molecule. The water molecule is also hydrogen bonded to
the
-carboxylate of Glu-488 (48). Removal of the 2-amino function is
expected to disrupt these three hydrogen bonds resulting in the loss of
3.0 kcal/mol of binding free energy observed when dGlc-6-P is the ligand. The amino group of GlcNol-6-P is hydrogen bonded to the carbonyl of Val-399 and a water molecule. The water molecule is also
hydrogen bonded to the
-amino group of Lys-603 (49). Removal of the
amino function from GlcNol-6-P is expected to disrupt these two
hydrogen bonding interactions resulting in the loss of 4.1 kcal/mol of
binding energy observed when dGlcol-6-P is the ligand. Therefore,
although the specific hydrogen bonding interactions between the amino
function and the protein appear to change when going from the
cis-enolamine intermediate-enzyme complex to the product-enzyme complex with the concomitant gain of a single hydrogen bond in the product-enzyme complex, the total binding affinity for the
amino function remains roughly unchanged. Once the structure of the
whole enzyme (glutamine amidotransferase and isomerase domains) is
solved, it will be interesting to see if the glutamine amidotransferase domain interacts with the amino function.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 1.
Binding of GlcN-6-P (panel
A) and GlcNol-6-P (panel B) to the active
site of GlmS. Stereograms of the respective enzyme bound ligands
are based on the coordinates of the crystallographic structures 1MOQ
and 1MOS (48, 49). Residue side chains, backbone carbonyls, and water
molecules relevant to binding of the amino and C1 hydroxyl groups are
displayed and labeled. The dotted lines indicate potential
hydrogen bonds as proposed in Refs. 48 and 49.
|
|
Thus, the interactions between GlmS and the 2-amino function of its
ligands are responsible for the uniform binding of the product and the
cis-enolamine intermediate as evidenced by the similar
contribution of the amino group to the free energy of binding of
GlcN-6-P and GlcNol-6-P, respectively. The amino function contributes
significantly to the free energy of binding both the product and the
reactive intermediate analogue, indicating that the 2-amino function is
an important moiety to be included in the design of carbohydrate-based
GlmS inhibitors.
 |
FOOTNOTES |
*
This work was supported by the Medical Research Council of
Canada through an operating grant (to S. L. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed.
2
The free energy of binding (
G) is
calculated using the equation
G = RTlnKi where T = 310.2 K
and R is the gas constant. The contribution of the amino
function to binding (
G) is calculated using the
equation 
G =
RTln(KiH/KiNH2)
where KiH and
KiNH2 represent
the competitive inhibition constants for ligands lacking and containing
the 2-amino function, respectively.
 |
ABBREVIATIONS |
The abbreviations used are:
GlmS, glucosamine-6-phosphate synthase;
Fru-6-P, D-fructose
6-phosphate;
GlcN-6-P, D-glucosamine 6-phosphate;
GlcNol-6-P, 2-amino-2-deoxy-D-glucitol 6-phosphate;
dGlcol-6-P, 2-deoxy-D-glucitol 6-phosphate;
dGlc-6-P, 2-deoxy-D-glucose 6-phosphate.
 |
REFERENCES |
| 1.
|
Ghosh, S.,
Blumenthal, H. J.,
Davidson, E.,
and Roseman, S.
(1960)
J. Biol. Chem.
235,
1265-1273[Free Full Text]
|
| 2.
|
Badet-Denisot, M.-A.,
René, L.,
and Badet, B.
(1993)
Bull. Soc. Chim. Fr.
130,
249-255
|
| 3.
|
Massière, F.,
and Badet-Denisot, M.-A.
(1998)
Cell. Mol. Life Sci.
54,
205-222[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Kort, M. J.
(1970)
Adv. Carbohydr. Chem. Biochem.
25,
311-349
|
| 5.
|
Golinelli-Pimpaneau, B.,
Le Goffic, F.,
and Badet, B.
(1989)
J. Am. Chem. Soc.
111,
3029-3034[CrossRef]
|
| 6.
|
Mei, B.,
and Zalkin, H.
(1990)
J. Bacteriol.
172,
3512-3514[Abstract/Free Full Text]
|
| 7.
|
Zalkin, H.
(1993)
Adv. Enzymol.
66,
203-309
|
| 8.
|
Denisot, M.-A.,
Le Goffic, F.,
and Badet, B.
(1991)
Arch. Biochem. Biophys.
288,
225-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Buchanan, J. M.
(1973)
Adv. Enzymol.
39,
91-183
|
| 10.
| Corizzi, V., Badet, B., and Badet-Denisot, M.-A. (1992) J. Chem. Soc. Chem. Commun. 189-190
|
| 11.
|
Badet-Denisot, M.-A.,
Leriche, C.,
Massière, F.,
and Badet, B.
(1995)
Bioorg. Med. Chem. Lett.
5,
815-820[CrossRef]
|
| 12.
|
Bearne, S. L.
(1996)
J. Biol. Chem.
271,
3052-3057[Abstract/Free Full Text]
|
| 13.
|
Leriche, C.,
Badet-Denisot, M.-A.,
and Badet, B.
(1997)
Eur. J. Biochem.
245,
418-422[Medline]
[Order article via Infotrieve]
|
| 14.
|
Leriche, C.,
Badet-Denisot, M.-A.,
and Badet, B.
(1996)
J. Am. Chem. Soc.
118,
1797-1798[CrossRef]
|
| 15.
|
Wolfenden, R.
(1972)
Acc. Chem. Res.
5,
10-18
|
| 16.
|
Wolfenden, R.
(1974)
Mol. Cell. Biochem.
3,
207-111[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Wolfenden, R.
(1976)
Annu. Rev. Biophys. Bioeng.
5,
271-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Wolfenden, R.,
and Frick, L.
(1987)
in
Enzyme Mechanisms
(Page, M. I.
, and Williams, A., eds)
, pp. 97-122, Royal Society of Chemistry, London
|
| 19.
|
Clark, J. M.,
and Switzer, R. L.
(1977)
Experimental Biochemistry
, 2nd Ed.
, p. 167, W. H. Freeman and Co., San Francisco, 310
|
| 20.
|
Finch, P.,
and Merchant, Z.
(1979)
Carbohydr. Res.
76,
225-232[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
| Finch, P., and Merchant, Z. (1975) J. Chem. Soc. Perkin
Trans. I 1682-1686
|
| 22.
|
Hockett, R. C.
(1935)
J. Am. Chem. Soc.
57,
2265-2268[CrossRef]
|
| 23.
|
Hockett, R. C.,
and Maynard, C. W.
(1939)
J. Am. Chem. Soc.
61,
2111-2115[CrossRef]
|
| 24.
|
Bearne, S. L.,
and Wolfenden, R.
(1995)
Biochemistry
34,
11515-11520[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Leloir, L. F.,
and Cardini, C. E.
(1957)
Methods Enzymol.
3,
840-850
|
| 26.
|
Chmara, H.,
Andruszkiewicz, R.,
and Borowski, E.
(1985)
Biochim. Biophys. Acta
870,
357-366
|
| 27.
|
Badet, B.,
Vermoote, P.,
and Le Goffic, F.
(1988)
Biochemistry
27,
2282-2287[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Kucharczyk, N.,
Denisot, M.-A.,
Le Goffic, F.,
and Badet, B.
(1990)
Biochemistry
29,
3668-3676[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Andruszkiewicz, R.,
Chmara, H.,
Milewski, S.,
and Borowski, E.
(1986)
Int. J. Peptide Res.
27,
449-453
|
| 30.
|
Auvin, S.,
Cochet, O.,
Kucharczyk, N.,
Le Goffic, F.,
and Badet, B.
(1991)
Bioorg. Chem.
19,
143-151[CrossRef]
|
| 31.
|
Milewski, S.,
Chmara, H.,
Andruszkiewicz, R.,
and Borowski, E.
(1992)
Biochim. Biophys. Acta
1115,
225-229[Medline]
[Order article via Infotrieve]
|
| 32.
|
Rose, I. A.
(1975)
Adv. Enzymol. Relat. Areas Mol. Biol.
43,
491-517[Medline]
[Order article via Infotrieve]
|
| 33.
|
Rose, I. A.
(1981)
Philos. Trans. R. Soc. Lond-Biol. Sci.
293,
131-143[Medline]
[Order article via Infotrieve]
|
| 34.
|
Farber, G. K.,
Glasfeld, A.,
Tiraby, G.,
Ringe, D.,
and Petsko, G. A.
(1989)
Biochemistry
28,
7289-7297[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Wolfenden, R.
(1970)
Biochemistry
9,
3404-3407[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Collins, K. D.
(1974)
J. Biol. Chem.
249,
136-142[Abstract/Free Full Text]
|
| 37.
|
Chirgwin, J. M.,
and Noltmann, E. A.
(1975)
J. Biol. Chem.
250,
7272-7276[Abstract/Free Full Text]
|
| 38.
|
Woodruff, W. W.,
and Wolfenden, R.
(1979)
J. Biol. Chem.
254,
5866-5867[Abstract/Free Full Text]
|
| 39.
|
Bigham, E. C.,
Gragg, C. E.,
Hall, W. R.,
Kelsey, J. E.,
Mallory, W. R.,
Richardson, D. C.,
Benedict, C.,
and Ray, P. H.
(1984)
J. Med. Chem.
27,
717-726[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Midelfort, C. F.,
and Rose, I. A.
(1977)
Biochemistry
16,
1590-1596[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Noltmann, E. A.
(1972)
Enzymes
6,
271-354
|
| 42.
|
Pierce, J.,
Serianni, A. S.,
and Barker, R.
(1985)
J. Am. Chem. Soc.
107,
2448-2456[CrossRef]
|
| 43.
|
Salas, M.,
Vinuela, E.,
and Sols, A.
(1965)
J. Biol. Chem.
240,
561-568[Free Full Text]
|
| 44.
|
Dyson, J. E. D.,
and Noltmann, E. A.
(1968)
J. Biol. Chem.
243,
1401-1414[Abstract/Free Full Text]
|
| 45.
|
Schray, K. J.,
Benkovic, S. J.,
Benkovic, P. A.,
and Rose, I. A.
(1973)
J. Biol. Chem.
248,
2219-2224[Abstract/Free Full Text]
|
| 46.
|
Gracy, R. W.,
and Noltmann, E. A.
(1968)
J. Biol. Chem.
243,
5410-5419[Abstract/Free Full Text]
|
| 47.
|
Oliva, G.,
Fontes, M. R.,
Garratt, R. C.,
Altamirano, M. M.,
Calcagno, M. L.,
and Horjales, E.
(1995)
Structure
3,
1323-1332[Medline]
[Order article via Infotrieve]
|
| 48.
|
Teplyakov, A.,
Obmolova, G.,
Badet-Denisot, M.-A.,
Badet, B.,
and Polikarpov, I.
(1998)
Structure
6,
1047-1055[Medline]
[Order article via Infotrieve]
|
| 49.
|
Teplyakov, A.,
Obmolova, G.,
Badet-Denisot, M.-A.,
and Badet, B.
(1999)
Protein Sci.
8,
596-602[Abstract]
|
| 50.
|
Jencks, W. P.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
4046-4050[Abstract/Free Full Text]
|
| 51.
|
Fersht, A. R.,
Shi, J.-P.,
Knill-Jones, J.,
Lowe, D. M.,
Wilkinson, A. J.,
Blow, D. M.,
Brick, P.,
Carter, P.,
Waye, M. M. Y.,
and Winter, G.
(1985)
Nature
314,
235-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Fersht, A.
(1999)
Structure and Mechanism in Protein Science
, pp. 340-345, W. H. Freeman and Co., New York
|
| 53.
|
Street, I. P.,
Armstrong, C. R.,
and Withers, S. G.
(1986)
Biochemistry
25,
6021-6027[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Kati, W. M.,
and Wolfenden, R.
(1989)
Science
243,
1591-1593[Abstract/Free Full Text]
|
| 55.
|
Santi, D. V.,
and Danenberg, P. V.
(1971)
Biochemistry
10,
4813-4820[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Mulivor, R.,
and Rappaport, H. P.
(1973)
J. Mol. Biol.
76,
123-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Holler, E.,
Rainey, P.,
Orme, A.,
Bennett, E. L.,
and Calvin, M.
(1973)
Biochemistry
12,
1150-1159[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Roestamadji, J.,
Grapsas, I.,
and Mobashery, S.
(1995)
J. Am. Chem. Soc.
117,
11060-11069[CrossRef]
|
| 59.
|
Albery, W. J.,
and Knowles, J. R.
(1976)
Biochemistry
15,
5631-5640[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Albery, W. J.,
and Knowles, J. R.
(1977)
Angew. Chem. Int. Ed. Engl.
16,
285-293[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Lolis, E.,
and Petsko, G. A.
(1990)
Annu. Rev. Biochem.
59,
597-630[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.